ArticleAnnals of medicine and surgery (2012)2026
Therapeutic potential of nerinetide in acute ischemic stroke: a comprehensive systematic review and meta-analysis.
Article in Annals of medicine and surgery (2012), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objectives: Acute ischemic stroke (AIS) is a leading cause of disability and death worldwide. Nerinetide, a neuroprotective peptide, has shown potential in limiting neuronal damage when administered early after stroke onset. This study aimed to evaluate the efficacy and safety of nerinetide compared with placebo in patients with AIS. Methods: A systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted in accordance with PRISMA and AMSTAR 2 guidelines. Electronic databases, including PubMed, MEDLINE, Cochrane Library, ScienceDirect, and ClinicalTrials.gov, were searched up to February 2025. The primary outcome assessed was mortality, while secondary outcomes included functional recovery (modified Rankin Scale, Barthel Index), infarct volume, and adverse events. Results: Three RCTs encompassing 2462 patients met the inclusion criteria. Nerinetide treatment demonstrated a modest yet statistically significant reduction in mortality risk (risk ratio = 0.86; Conclusion: Nerinetide may slightly reduce mortality in AIS, particularly among patients not treated with alteplase. Although functional outcomes did not significantly improve, its favorable safety profile and potential neuroprotective effect support further investigation in larger clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.